Trial Profile
Phase 1 trial of a selective orexin 1 receptor antagonist ACT-539313 in healthy male subjects: A first-in-human randomized, double-blind single-ascending dose study
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Feb 2020
Price :
$35
*
At a glance
- Drugs Nivasorexant (Primary)
- Indications Anxiety disorders
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
- 17 Feb 2020 Results published in the British Journal of Clinical Pharmacology
- 24 Mar 2018 Status changed from recruiting to completed according to results presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 24 Mar 2018 Results presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics